PabloMTebasMD

PubMed

• Cognate antigen engagement induces HIV-1 expression in latently infected CD4T cells from people on long-term antiretroviral therapy.
  Milica Moskovljevic, Filippo Dragoni, Nathan L Board, Fengting Wu, Jun Lai
  Immunity. 2024-12-10
• National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned.
  Roy M Gulick, Alice K Pau, Eric Daar, Laura Evans, Rajesh T Gandhi
  Annals of Internal Medicine. 2024-11-01
• 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart f...
  Adarsh Bhimraj, Yngve Falck-Ytter, Arthur Y Kim, Jonathan Z Li, Lindsey R Baden
  Clinical Infectious Diseases. 2024-10-29

Journal Articles

• The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Post-Treatment Controllers Identified from 14 Clinical Studies  
  Elizabeth Connick, Michael C Sneller, Jonathan Z Li, Paul Volberding, Daniel R Kuritzkes, Robert T Schooley, David Margolis, Daniel Skiest, John W Mellors, Ronald Mits..., The Journal of Infectious Diseases
• HIV-1 Latent Reservoir Size and Diversity Are Stable Following Brief Treatment Interruption  
  Robert F. Siliciano, Jonathan Z. Li, Katharine J. Bar, James Hoxie, Pablo Tebas, The Journal of Clinical Investigation
• A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infec...  
  Huhn, G. D., Tebas, P., Gallant, J., Wilkin, T., Cheng, A., Yan, M., Zhong, L., Callebaut, C., Custodio, J. M., Fordyce, M. W., Das, M., McCallister, S., J Acquir Immune Defic Syndr, 1/1/2017
• Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis  
  Koenig, H. C., Mounzer, K., Daughtridge, G. W., Sloan, C. E., Lalley-Chareczko, L., Moorthy, G. S., Conyngham, S. C., Zuppa, A. F., Montaner, L. J., Tebas, P., HIV Med, 1/1/2017
• Current use of statins reduces risk of HIV rebound on suppressive HAART  
  Drechsler, H., Ayers, C., Cutrell, J., Maalouf, N., Tebas, P., Bedimo, R., PLoS One, 1/1/2017
• The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection  
  Jacobson JM, Zheng L, Wilson CC, Tebas P, Matining RM, Egan MA, Eldridge J, Landay AL, Clifford DB, Luetkemeyer AF, Tiu J, Martinez AL, Janik J, Spitz TA, Hural J, McE..., J Acquir Immune Defic Syndr, 1/1/2016
• The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1  
  Jacobson JM, Bosinger SE, Kang M, Belaunzaran-Zamudio P, Matining RM, Wilson CC, Flexner C, Clagett B, Plants J, Read S, Purdue L, Myers L, Boone L, Tebas P, Kumar P, ..., AIDS Research and Human Retrovirus, 1/1/2016
• Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy ...  
  Overton ET, Tebas P, Coate B, Ryan R, Perniciaro A, Dayaram YK, De La Rosa G, Baugh BP, HIV clinical trials, 1/1/2016
• Brief Report: A Randomized, Double-Blind comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil fumarate (TDF), each coformulated with Elvitegravir, Cobicis...  
  Wohl D, Oka S, Clumeck N, Clarke A, Brinson C, Stephens J, Tashima K, Arribas JR, Rashbaum B, Cheret A, Brunetta J, Mussini C, Tebas P, Sax PE, Cheng A, Zhong L, Calle..., J Acquir Immune Defic Syndr, 1/1/2016
• Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and...  
  Wohl, D., Oka, S., Clumeck, N., Clarke, A., Brinson, C., Stephens, J., Tashima, K., Arribas, J. R., Rashbaum, B., Cheret, A., Brunetta, J., Mussini, C., Tebas, P., Sax..., J Acquir Immune Defic Syndr, 1/1/2016
• Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption  
  Bar, K. J., Sneller, M. C., Harrison, L. J., Justement, J. S., Overton, E. T., Petrone, M. E., Salantes, D. B., Seamon, C. A., Scheinfeld, B., Kwan, R. W., Learn, G. H..., N Engl J Med, 1/1/2016
• Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a...  
  Post Frank A, Tebas Pablo, Clarke Amanda, Cotte Laurent, Short William, Abram Michael E, Jiang Shuping, Cheng Andrew, Das Moupali, Fordyce Marshall W, Journal of acquired immune deficiency syndromes, 1/1/2016
• A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"?  
  Lederman MM, Cannon PM, Currier JS, June CH, Kiem HP, Kuritzkes DR, Lewin SR, Margolis DM, McCune JM, Mellors JW, Schacker TW, Sekaly RP, Tebas P, Walker BD, Douek DC, Pathogens & immunity, 1/1/2016
• Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1  
  Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang J C, German P, Dvory-Sob..., N Engl J Med, 1/1/2015
• Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial  
  Overton ET, Chan ES, Brown TT, Tebas P, McComsey GA, Melbourne KM, Napoli A, Hardin WR, Ribaudo HJ, Yin MT, Ann Intern Med, 1/1/2015
• Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected Women  
  Lo Re, V., 3rd, Lynn, K., Stumm, E. R., Long, J., Nezamzadeh, M. S., Baker, J. F., Hoofnagle, A. N., Kapalko, A. J., Mounzer, K., Zemel, B. S., Tebas, P., Kostman, J. ..., J Infect Dis, 1/1/2015
• Superior outcomes in HIV-positive kidney transplant patients compared with HCV-infected or HIV/HCV-coinfected recipients  
  Sawinski, D., Forde, K. A., Eddinger, K., Troxel, A. B., Blumberg, E., Tebas, P., Abt, P. L., Bloom, R. D., Kidney Int, 1/1/2015
• Synthetic Consensus HIV-1 DNA Induces Potent Cellular Immune Responses and Synthesis of Granzyme B, Perforin in HIV Infected Individuals  
  Morrow, M. P., Tebas, P., Yan, J., Ramirez, L., Slager, A., Kraynyak, K., Diehl, M., Shah, D., Khan, A., Lee, J., Boyer, J., Kim, J. J., Sardesai, N. Y., Weiner, D. B...., Mol Ther, 1/1/2015
• Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults  
  Tebas P, Spitsin S, Barrett JS, Tuluc F, Elci O, Korelitz JJ, Wagner W, Winters A, Kim D, Catalano R, Evans DL, Douglas SD, AIDS, 1/1/2015
• Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients  
  Bedimo, R., Kang, M., Tebas, P., Overton, E. T., Hollabaugh, K., McComsey, G., Bhattacharya, D., Evans, C., Brown, T. T., Taiwo, B., AIDS Res Hum Retroviruses, 1/1/2015
• Lipid Levels and Changes in Body Fat Distribution in Treatment-Naive, HIV-1-Infected Adults Treated With Rilpivirine or Efavirenz for 96 Weeks in the ECHO and THRIVE T...  
  Tebas, P., Sension, M., Arribas, J., Duiculescu, D., Florence, E., Hung, C. C., Wilkin, T., Vanveggel, S., Stevens, M., Deckx, H., on behalf of the, Echo, Thrive Study..., Clin Infect Dis, 1/1/2014
• A Protocol Team: A Randomized Controlled Trial of Palifermin (Recombinant Human Keratinocyte Growth Factor) for the Treatment of Inadequate CD4+ T-Lymphocyte Recovery ...  
  Jacobson, J. M., Wang, H., Bordi, R., Zheng, L., Gross, B. H., Landay, A. L., Spritzler, J., Routy, J. P., Benson, C., Aberg, J., Tebas, P., Haas, D. W., Tiu, J., Coug..., J Acquir Immune Defic Syndr, 1/1/2014
• Seroprotection of HIV-infected subjects after influenza A(H1N1) vaccination is directly associated with baseline frequency of naive T cells  
  Ramirez, L. A., Daniel, A., Frank, I., Tebas, P., Boyer, J. D., J Infect Dis, 1/1/2014
• The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in anti...  
  Bedimo, R. J., Drechsler, H., Jain, M., Cutrell, J., Zhang, S., Li, X., Farukhi, I., Castanon, R., Tebas, P., Maalouf, N. M., PLoS One, 1/1/2014
• Modeling and simulation approach to support dosing and study design requirements for treating HIV-related neuropsychiatric disease with the NK1-R antagonist aprepitant  
  Barrett, J. S., Bajaj, G., McGuire, J., Wu, D., Spitsin, S., Moorthy, G., Zhao, X., Tebas, P., Evans, D. L., Douglas, S. D., Curr HIV Res, 1/1/2014
• Join now to see all

Books/Book Chapters

• AIDS Therapy. 
  Chapter: Bone diseases and HIV infection. 
  Amorosa, V.; Tebas P.Churchill Livingstone, Philadelphia, PA2007
• Human Virus Guides. Human Immunodeficiency Virus. 
  Chapter: Clinical Manifestations of HIV Infection. 
  Powderly, WG, Tebas, P.International Medical Press, London, United Kingdom2003
• Manual of Medical Therapeutics. The Washington Manual. 
  Chapter: HIV/ADIS. 
  P. Tebas, W. TantisiviwatLippincott-Raven Publishers, Philadelphia, PAEdition 30th,2001
• Manual of Medical Therapeutics. The Washington Manual. 
  Chapter: The immunocompromised Host. 
  Tebas P, Horgan M.Lippincott-Raven Publishers, Philadelphia, PAEdition 29th,1998
• Powderly WG "Manual of HIV therapeutics". 
  Chapter: Primary care of the HIV infected patient. 
  Tebas P, Horgan M., Powderly WGLippincott-Raven Publishers, Philadelphia, PA1997
• Core Curriculum in Infection Control 
  Chapter: Mycobacterium tuberculosis infections and non tuberculosis mycobacterium. 
  Tebas P, Fraser V.Editors: Olmstead R.Mosby Year Book Inc.1996
• Join now to see all

Abstracts/Posters

• Pegylated IFN-alpha-2b decreases latent HIV measures in art-suppressed subjects.
  Azzoni, L., Papasavvas, E., Chomont, N., Li, Q., Howell, B. J., Richman, D. D., Tebas, P., Mounzer, K., Kostman, J., Montaner, L., Conference on Retrovirus and Opportunistic Infections, Seattle, WA, 1/13/2017
• Bone microarchitectural changes and fracture-risk prediction in HIV and HCV.
  Bedimo, R., Adams-Huet, B., Poindexter, J., Farukhi, I., Castanon, R., Brown, G., Turner, D., Moore, T., Tebas, P., Maalouf, N., Conference on Retrovirus and Opportunistic Infections, Seattle, WA, 1/13/2017
• Urine tenofovir testing to measure PrEP adherence among youth in a real world setting.
  Lalley-Chareczko, L., Clark, D., Moorthy, G. S., Zuppa, A., Conyngham, C., Mounzer, K., Tebas, P., Koenig, H. C., Conference on Retrovirus and Opportunistic Infections, Seattle, WA, 1/13/2017
• Current statin use reduces risk of viral rebound on suppressive cart.
  Drechsler, H. J., Ayers, C., Cutrell, J., Maalouf, N., Tebas, P., Bedimo, R., Conference on Retrovirus and Opportunistic Infections, Seattle, WA, 1/13/2017
• Evolution of HIV-1 resistance to the fusion inhibitor C34-CXCR4 and potential fitness costs in consideration of a phase 1 clinical trial.
  Leslie, G. J., Haggarty, B., Romano, J., Jordon, A. P. O., Wang, J., Richardson, M. W., Riley, J. L., Holmes, M. C., Tebas, P., Hoxie, J., 20th Annual Meeting of the American Society of Gene and Cell Therapy, Washington, DC, 1/10/2017
• Intradermal Delivery of INO-4201 Drives Robust Ebola Glycoprotein Specific Humoral and Cellular Immune Responses in Healthy Volunteers in an Open Label Phase I Trial.
  Kraynyak, K. A., Amante, D., Tebas, P., Knoblock, D., Sylvester, A. J., Morrow, M. P., Prostak, N., Liu, L., Sakata, L., Cheung, J., Desfor, S., Patel, A., Dallas, M.,..., 104th Annual Meeting of the American Association of Immunologists, Washington, DC, 1/1/2017
• Bone outcomes with EFV+TDF/FTC versus other TDF-containing antiretroviral regimens among HIV-infected veterans: A US national study.
  LaFleur, J., Bress, A., Myers, J., Rosenblatt, L., Crook, J., Nyman, H., Bedimo, R., Tebas, P., Esker, S., International Congress on Drug Therapy in HIV Infection, Glasgow, United Kingdom, 1/23/2016
• IFN-a Augments NK-Mediated ADCC Lysis via VRC01 or HIV-1 Infected Subject Plasma.
  Tomescu, C., Ross, B., Tebas, P, Montaner, L., 23rd Conference on Retrovirus and Opportunisitc Infections, Boston, MA, 1/22/2016
• Racial Differences in Bioavailable Vitamin D With Supplementation: ACTG A5280.
  Yin M, Chan E, Brown T, Tebas P, McComsey G, Melbourne K, Hardin R, Ribaudo H, Overton, E, 23rd Conference on Retrovirus and Opportunisitc Infections, Boston, MA, 1/22/2016
• Longer-Term Safety of Tenofovir Alafenamide in Renal Impairment.
  Post, F. A., Tebas, P, Clarke, A., Cotte, L., Short, W., Abram, M. E., Shuping, J., Cheng, A., Das, M., Fordyce, M., 23rd Conference on Retrovirus and Opportunisitc Infections, Boston, MA, 1/22/2016
• Reduced Rectal HIV RNA After Peg-IFN-a2b Added to ART Together With ART Interruption.
  Papasavvas, E. , Kang, G. , Azzoni, L., Aberra, F., Tebas, P., Mounzer, K., Kostman, J., Richman, D., Qingsheng, L., Montaner, L., 23rd Conference on Retrovirus and Opportunisitc Infections, Boston, MA, 1/22/2016
• Aspirin Fails to Impact Immune Activation or Endothelial Function in Treated HIV.
  O'brian M, Kitch D, Hunt P, Klingman K, Stein JH, Funderburg NT, Berger JS, Tebas P, Aberg J, 23rd Conference on Retrovirus and Opportunisitc Infections, Boston, MA, 1/22/2016
• ACTG 5340:The Effect of VRC01 on Viral Kinetics After Analytic Treatment Interruption.
  Bark, KJ, Harrison, L., Overton, E, Bardsley, M, Messer, M, Capparelli, E, Graham, B, Koup, RA, Hoxie, J, Tebas, P, 23rd Conference on Retrovirus and Opportunisitc Infections, Boston, MA, 1/22/2016
• Vitamin D Supplementation Does Not Affect Metabolic Changes Seen With ART Initiation.
  Brown, T., Chan, E., Ribaudo, H. , Overton, E., Tebas, P., Melbourne, K. , Hardin, R., Yin, M., 22nd Conference on Retrovirus and Opportunisitc Infections, Seattle, WA, 1/23/2015
• Associations Between Plasma Cytokine and Microbial Translocation Biomarkers and IRIS.
  Harrison, L., Tierney, C., Fischl, M., George, V., Roach, M., Pahwa, S., Li X.D., Asmuth, D., Tebas, P., Godfrey, C., 22nd Conference on Retrovirus and Opportunisitc Infections, Seattle, WA, 1/23/2015
• Urine Assay for Tenofovir to Monitor Adherence to Tenofovir-Emtricitabine as PrEP.
  Koenig H, Mounzer K, Daughtridge G, Sloan C, Ketner E, Lalley-Chareczko L, Conyngham SC, Moorthy G, Montaner L, Tebas P, 22nd Conference on Retrovirus and Opportunisitc Infections, Seattle, WA, 1/23/2015
• Azzoni L, Papasavvas E, Lynn KM, Kapalko A, Lalley-Chareczko L, Aberra F, Tebas P, Mounzer KC, Kostman JR, Li Q, Montaner LJ, 8th IAS Conference on HIV pathogenesis, Treatment and Prevention, 1/1/2015
• Strategic Simplification: The Efficacy and Safety of Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) plus Darunavir (DRV) in Treat...
  Huhn G, Tebas P, Gallant J, Wilkin T, Cheng A, Yan M, Callebaut C, Fordyce M, Das M, Mccallister S, IDWeek, San Diego, CA, 1/1/2015
• Evaluation and management of fracture risk in HIV patients in the VA system.
  Cutrell J, Zhang S, Drechsler H, Tebas P, Maalouf N, Bedimo R, 8th IAS Conference on HIV pathogenesis, Treatment and Prevention, 1/1/2015
• Structural Bone Deficits in HIV/HCV, HCV-Monoinfected, and HIV-Monoinfected Women.
  Lo Re III, V. , Lynn, K. , Stumm,E. , Long, J. , Nezamzadeh,M. , Baker,J. , Kapalko,A. , Mounzer,K. , Tebas,P. , Kostman,J. , Leonard,M., IDWeek, Philadelphia, PA, 1/8/2014
• Impact of IGF-1 and Sex Steroids on Bone Health in HIV- and HCV-Infected US Male Veterans.
  Cutrell, J. , Maalouf, N. , Zhang, S. , Carvour, M. , Drechsler, H. , Tebas, P. , Bedimo, R., IDWeek, Philadelphia, PA, 1/8/2014
• The Effects of Interferon/Ribavirin Therapy on Bone Turnover Markers (BTMs) in HIV/HCV Co-Infected Subjects.
  Bedimo , R. , Kang, M. , Tebas, P. , Overton, E. , Hollabaugh, K. , McComsey,G. , Bhattacharya, D. , Evans, C. , Brown, T. , Taiwo, B., ICAAC, Washington, DC, 1/5/2014
• The 2013 AHA/ACC Pooled Cohort Risk Equations perform better than Framingham score but still underestimate CVD risk in HIV+ Veterans.
  Drechsler , H. J. , Ayers, C. , Cutrell, J. , Maalouf, N. , Tebas, P. , Bedimo, R., ICAAC, Washington, DC, 1/5/2014
• Simplification of PI+RTV+FTC/TDF To E/C/F/TDF Maintains HIV Suppression and Is Well Tolerated.
  Arribas,J., Pialoux,G., Gathe,J., Di Perri,G., Reynes,J., Tebas,P., Nguyen,T., Ebrahimi,R., White,K., Piontkowsky,D., 21st Conference on Retrovirus and Opportunisitc Infections, Boston, MA, 1/3/2014
• Reduction of sCD163, SP and PD1+ Th Cell Levels in a Phase 1B Trial of the NK1R Antagonist Aprepitant.
  Tebas, P., Spitsin, S., Barrett, J., Tuluc, F. , Elci,O., Korelitz,J., Wagner,W., Kim,D., Catalano,R., Douglas,S.D., 21st Conference on Retrovirus and Opportunisitc Infections, Boston, MA, 1/3/2014
• Join now to see all

Lectures

• Efforts and advances for the HIV Cure. 
  San Juan, Puerto Rico - 1/29/2017
• Frotiers in HIV 
  1/1/2017
• Clinical Trials: Triumphs and Tribulations. Efforts to cure HIV 
  University of Cincinnati, OH - 1/1/2017
• On the Road to Curing HIV 
  Philadelphia, PA - 1/1/2017
• Current studies aiming for the "cure" at Penn and Wistar Institute 
  Philadelphia, PA - 1/1/2017
• Contemporary Management of HIV: Antiretroviral Therapy as Prevention 
  New York, NY - 1/1/2017
• Contemporary Management of HIV: Best Practices for ART Management and Optimizing Outcomes in Persons of Color 
  New York, NY - 1/1/2017
• Contemporary Management of HIV: Managing HIV in Viral Hepatitis Coinfection 
  Howard University, Washington, DC - 1/1/2017
• Managing Fatty liver in HIV infected patient 
  Mexico City, Mexico - 1/28/2016
• Management of HCV and HIV co-infection 
  Santa Cruz, Bolivia - 1/1/2016
• Autologous Stem Cell transplantation 
  New York, NY - 1/1/2016
• The future of Infectious Diseases 
  Barcelona, Spain - 1/1/2016
• Bone Disease and HIV 
  Dallas, TX - 1/1/2016
• Retos actuales en la Infeccion for VIH. 
  Madrid, Spain - 1/1/2015
• Challenges in HIV Treatment Antiretroviral Options & Patient Differences. As time goes by: Aging with HIV 
  Mexico City - 1/1/2015
• Challenges in HIV Treatment Antiretroviral Options & Patient Differences. Fat and unfit: HIV and Metabolic Syndrome 
  Mexico City - 1/1/2015
• Terapia Genetica para el tratamiento del VIH 
  Clinica Puerta de Hierro de Madrid, Spain - 1/1/2015
• What Are We Doing to Cure HIV? 
  1/1/2015
• Curing HIV: Gene Therapy and Other Approaches to cure HIV 
  1/1/2015
• Therapy Approaches for HIV 
  San Diego, CA - 1/1/2014
• First Line Therapy for HIV infection, 3er Agente de Inicio: ITRNN vs INSTI vs IP 
  Guadalajara, Mexico - 1/1/2014
• Gene Editing with CCR5-Targeted Zinc Finger Nucleases. Strategies for an HIV Cure 
  NIH, Bethesda, MD - 1/1/2014
• Se puede curar el VIH? 
  Malaga, Spain - 1/1/2014
• Boosted Protease Inhibitors: Current and Future Role in HIV Therapy 
  Chapel Hill, NC - 1/1/2014
• Gene Therapy Approaches towards HIV Cure 
  1/10/2013
• Join now to see all

Other

• Individualizing HIV Care In Light of Cardiovascular Risk 
  Tebas P
  http://clinicaloptions.com/hiv/manage/cardio/
  1/1/2003
• Solid organ transplantation in HIV-infected individuals. Notes: A continuous update on the topic in Uptodate. 
  Tebas P
  www.uptodate.com
  1/1/2003
• When to start antiretroviral therapy. The case for caution. 
  Tebas P, Medscape
  http://www.medscape.com/viewarticle/418271_1
  1/1/2002
• Notes: A forum for patients with HIV infection that is run in Spanish. 
  Tebas P, The body.com
  www.thebody.com
  1/1/2000
• Join now to see all